for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

Sartorius confirms 2022 outlook as pandemic effects, order intake normalise

FRANKFURT, April 21 (Reuters) - Franco-German lab supplies group Sartorius AG confirmed its 2022 outlook on Thursday as pandemic-related effects and the development of order intake were normalising as expected in the first quarter.

Sartorius, which competes in bioreactor gear with Merck KGaA and Thermo Fisher, said underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) was 349 million euros ($378.28 million).

The corresponding underlying EBITDA margin improved to 34.1%, said the company.

The company, which last year entered Germany’s blue-chip index DAX, has guided for 2022 group sales to increase by about 15% to 19%, at constant foreign exchange rates, and for the underlying EBITDA margin to match last year’s level of about 34%. ($1 = 0.9226 euros) (Reporting by Ludwig Burger; Writing by Miranda Murray; Editing by Muralikumar Anantharaman)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up